Dimerix Ltd has released a press release.
ACTION3 Clinical Trial Milestone Recruitment Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- 1st ACTION3 site in Japan activated and milestone triggered
- Successful planned IDMC review of ACTION3 trial
- Dimerix receives initial upfront payment from Amicus
- Investor Webinar and Presentation
- Dimerix Licenses DMX-200 in the US
Later from Dimerix
- Dimerix receives 1st Development Milestone payment from FUSO
- Appendix 4E and 2025 Annual Report
- DMX-200 receives Orphan Drug Designation in Japan
- Successful PARASOL Collaboration Data Analysis Outcome
- Successful Completion of Planned IDMC Review
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix